Node Status
Live
Node Status
Learning Objectives
About ADR
Sub Nodes
- Types of ADR of TB Treatment
- Management of Adverse Drug Reactions(ADRs) of TB Treatment
- Adverse Drug Reactions(ADRs) to First Line Treatment
- Adverse Drug Reactions(ADRs) to Second Line Treatment
- Management of DR-TB ADR: Gastrointestinal Symptoms [Gastritis and abdominal pain]
- Management of DR-TB ADR: Diarrhoea and/or Flatulence
- Management of DR-TB ADR: Giddiness
- Management of DR-TB ADR: Hematological Abnormalities
- Management of DR-TB ADR: Hypothyroidism
- Management of DR-TB ADR: Arthralgia
- Management of DR-TB ADR: Depression
- Management of DR-TB ADR: Psychotic Symptoms
- Management of DR-TB ADR: Suicidal Ideation
- Management of DR-TB ADR: Seizures
- Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity]
- Management of DR-TB ADR: Gynecomastia
- Management of DR-TB Patients: Lost to Follow-up
- Drugs Used in the Management of Adverse Events
- Rationale for Grouping of Anti-TB Drugs
- Drugs Not Included in Groups A - C and Rationale for Non-inclusion
- Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment
- Bedaquiline Drug Dosages and Duration
- Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment
- Delamanid [Dlm] Drug Dosages and Duration
- Pre-treatment Evaluation [PTE] of DR-TB Patients
- Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up
- DR-TB Treatment in Pregnancy: General Considerations
- Immune Reconstitution Inflammatory Syndrome [IRIS]
- Common or Relevant Adverse Effects of DR-TB Therapy
- Management of QT Prolongation by Grade of Severity of ADR
- Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen
- State PMDT Committee: Terms of Reference [ToR]
- State Airborne Infection Control [AIC] Committee: Terms of Reference [ToR]
- Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen
- Methods for Pharmacovigilance Activity Reporting [aDSM]
- Causality Assessment for ADR Reporting
- Causality Assessment: WHO-UMC [UPSALA Monitoring Centre] Causality Categories for ADR Reporting
- Severity Criteria for Reporting ADRs
- Management of DR-TB ADR: Metallic Taste
- Classification of Adverse Drug Events
- Active TB Drug Safety Monitoring [aDSM]
- Adverse Event Definitions and Classifications
- Reporting of Adverse Events and Serious Adverse Events